Nutra Pharma Corp (NPHC) Total Debt (2010 - 2026)

Nutra Pharma has disclosed Total Debt across 17 years of filings, most recently posting $2.2 million for Q2 2026.

• In Q2 2026, Total Debt fell 79.13% year-over-year to $2.2 million; the TTM figure through Jun 2026 stood at $2.2 million (down 79.13% YoY), while the FY2025 annual figure was $10.7 million, up 14.8% from the prior year.
• Total Debt came in at $2.2 million for Q2 2026 at Nutra Pharma, up from $1.2 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $17.5 million in Q2 2024 to a low of $1.2 million in Q1 2026.
• Average Total Debt over 5 years is $12.3 million, with a median of $12.5 million recorded in 2022.
• Year-over-year, Total Debt surged 76.5% in 2023 and slumped 88.53% in 2026.
• Over 5 years, Total Debt stood at $9.9 million in 2022, then surged by 76.5% to $17.5 million in 2023, then tumbled by 46.52% to $9.3 million in 2024, then climbed by 14.8% to $10.7 million in 2025, then sank by 79.74% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $2.2 million in Q2 2026, $1.2 million in Q1 2026, and $10.7 million in Q4 2025.